Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04659044
Title Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United

mantle cell lymphoma

marginal zone B-cell lymphoma

follicular lymphoma

chronic lymphocytic leukemia/small lymphocytic lymphoma


Polatuzumab vedotin-piiq + Rituximab + Rituximab Hyaluronidase + Venetoclax

Rituximab Hyaluronidase + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.